1) the poor production capacity of China's drug research and development, the good point of the drug are imported, not expensive, a lot of U.S. medicines and devices, the domestic sale than the U.S. are more expensive.
2) There are too many distribution links, too many hands wanting to dip their hands in the oil and water, and the doctors are just the weakest link you can see, being exposed as soon as something happens to be pushed out as a shield; it's the ones hidden in the back that are the big ones.
Well, that's just how dumb it is.
It's assumed that when drug prices are lowered, there are fewer kickbacks for doctors, so there's less incentive for them to overmedicate - but there isn't.
It depends on a number of factors, how competitive the drugs are, the profit margins of the manufacturers, etc. The impact on drug rebates in the long run is unknown, and the probable event is that there will be an overall reduction in drug rebates.
While outpatient prices have gone up, outpatient charges are not high and do not account for a large proportion of hospital revenue. After the abolition of drug markups and a decline in testing costs, overall hospital revenue is down, and the rise in outpatient revenue does not offset the decline in other revenue, and the state does not increase subsidies as a result.
The overall revenue of hospitals is not rising in the environment, the doctor will be because of the price increase in outpatient fees and the basic possibility of income unchanged or rising is very small. Of course the share of a single visit is certainly more than before, so it is really intoxicating to have a knowledgeable user say that some doctors have to make a single visit into several visits!
Of course, there are departments with increased benefits, such as oncology radiotherapy departments, because the main medical services, the price increase is medical services ah. At present, the departments that benefit from health care reform are very few.
Of course, after the price hike, our outpatient fees are still not expensive, and the outpatient experience is really bad. These are two issues that are hard to reconcile at the same time; it can't always be cheap and good, not in accordance with basic principles.
Assuming that doctors' incomes are largely based on drug rebates, then after doctors' incomes increase due to higher outpatient fees, doctors will suddenly exercise self-ethical restraint and not over-prescribe and over-medicate - but they won't.
China's drug-based medicine has its own background and motivation to begin with, but by now it has become a basic unspoken rule. Even if doctors' sunshine income rises dramatically, it won't necessarily change the habit of taking kickbacks. Changing this will take a systematic, long-term effort, not self-discipline or morality on the part of doctors.
The United States, Japan, Taiwan and other places have experienced this situation in China, and it took a long time to change. On the one hand, they have raised the sunshine income of doctors, on the other hand, they have strict various review and punishment mechanisms, and on the other hand, they have practiced elite education to raise the threshold of entry for doctors.